These reports built upon previous whole-exome and targeted sequencing projects that identified mutually exclusive genomic drivers in up to 80% of cases11,12,14, including previously unknown neoplasia genes such as POLR2A, KLF4, and TRAF7. However, despite a growing understanding of which patients harbor aggressive lesions, the genomic drivers of one-fifth of patients have remained obscure, preventing the use of precision medications with high efficacy. Here, TRAF7 is linked to neoplasm.